Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | LIPA | P38571 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392079 | 0.88 | EPHX1 (0.31) | TDP1ALOX5ALDH1A1 | |
| SCHEMBL27726415 | 0.84 | ROCK2 (0.34) | ROCK2ROCK1TDP1LMNAALOX5 | |
| SCHEMBL14576723 | 0.83 | LIPA (0.38) | TDP1LMNAALOX5ALDH1A1ANPEP | |
| SCHEMBL526891 | 0.83 | — | — | |
| SCHEMBL15043693 | 0.83 | LIPA (0.38) | TDP1LMNAALOX5ALDH1A1ANPEP | |
| SCHEMBL939908 | 0.83 | ANPEP (0.47) | ROCK2ROCK1TDP1LMNAALDH1A1 | |
| SCHEMBL10232799 | 0.83 | ANPEP (0.47) | ROCK2ROCK1TDP1LMNAALDH1A1 | |
| SCHEMBL939910 | 0.83 | ANPEP (0.47) | ROCK2ROCK1TDP1LMNAALDH1A1 | |
| SCHEMBL10406499 | 0.82 | — | — | |
| SCHEMBL24483919 | 0.81 | ROCK2 (0.33) | ROCK2ROCK1TDP1LMNAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252883-A1 | Macrocycles and Their Uses | NOVARTIS AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-8476224-B2 | Macrocycles and their uses | NOVARTIS AG (US) | 2013-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252883-A1 | Macrocycles and Their Uses | MRPL21, CLPP, MLEC | ROCK2 2204/4885ROCK1 2782/4885TDP1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.